Literature DB >> 3740914

Use of human growth hormone in treatment of nesidioblastosis in a neonate.

M D Hocking, S J Newell, P H Rayner.   

Abstract

Growth hormone was effective in reducing the glucose requirement in an infant with nesidioblastosis. He was suffering from fluid overload secondary to glucose and water infusions necessary to maintain blood glucose. Early pancreatectomy is the preferred treatment in severe cases, but human growth hormone has a place in preoperative management.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3740914      PMCID: PMC1777864          DOI: 10.1136/adc.61.7.706

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  CONTROL OF HYPOGLYCAEMIA WITH DIAZOXIDE AND HUMAN GROWTH HORMONE.

Authors:  M ERNESTI; M L MITCHELL; M S RABEN; Y GILBOA
Journal:  Lancet       Date:  1965-03-20       Impact factor: 79.321

2.  Evaluation of tri-iodothyronine in the treatment of acute alcoholic intoxication.

Authors:  H KALANT; G SERENY; R CHARLEBOIS
Journal:  N Engl J Med       Date:  1962-07-05       Impact factor: 91.245

3.  Complications of diazoxide in the treatment of nesidioblastosis.

Authors:  M E McGraw; D A Price
Journal:  Arch Dis Child       Date:  1985-01       Impact factor: 3.791

4.  Complications of diazoxide in the treatment of nesidioblastosis.

Authors:  D R Gillies
Journal:  Arch Dis Child       Date:  1985-05       Impact factor: 3.791

5.  Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia.

Authors:  A Aynsley-Green; J M Polak; S R Bloom; M H Gough; J Keeling; S J Ashcroft; R C Turner; J D Baum
Journal:  Arch Dis Child       Date:  1981-07       Impact factor: 3.791

  5 in total
  1 in total

1.  Somatostatin analogue in short term management of hyperinsulinism.

Authors:  S J Newell; M D Hocking; P H Rayner
Journal:  Arch Dis Child       Date:  1989-05       Impact factor: 3.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.